Macular degeneration (age-related) - pegaptanib and ranizumab: appeal from Pfizer Pfizer: appeal received Pfizer: initial scrutiny letter Pfizer: response to scrutiny letter Pfizer: final scrutiny letter This page was last updated: 30 March 2010